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Abstract
Although host genetics influences susceptibility to tuberculosis (TB), few genes determining disease outcome have been
identified. We hypothesized that macrophages from individuals with different clinical manifestations of Mycobacterium
tuberculosis (Mtb) infection would have distinct gene expression profiles and that polymorphisms in these genes may also
be associated with susceptibility to TB. We measured gene expression levels of .38,500 genes from ex vivo Mtb-stimulated
macrophages in 12 subjects with 3 clinical phenotypes: latent, pulmonary, and meningeal TB (n=4 per group). After
identifying differentially expressed genes, we confirmed these results in 34 additional subjects by real-time PCR. We also
used a case-control study design to examine whether polymorphisms in differentially regulated genes were associated with
susceptibility to these different clinical forms of TB. We compared gene expression profiles in Mtb-stimulated and
unstimulated macrophages and identified 1,608 and 199 genes that were differentially expressed by .2- and .5-fold,
respectively. In an independent sample set of 34 individuals and a subset of highly regulated genes, 90% of the microarray
results were confirmed by RT-PCR, including expression levels of CCL1, which distinguished the 3 clinical groups.
Furthermore, 6 single nucleotide polymorphisms (SNPs) in CCL1 were found to be associated with TB in a case-control
genetic association study with 273 TB cases and 188 controls. To our knowledge, this is the first identification of CCL1 as a
gene involved in host susceptibility to TB and the first study to combine microarray and DNA polymorphism studies to
identify genes associated with TB susceptibility. These results suggest that genome-wide studies can provide an unbiased
method to identify critical macrophage response genes that are associated with different clinical outcomes and that
variation in innate immune response genes regulate susceptibility to TB.
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Introduction
TB, a leading cause of death worldwide, is characterized by
different clinical forms including latent TB (LTB), localized
pulmonary infection, and various forms of extrapulmonary TB
including TBM. 90% of people infected with Mtb have latent
infection with no symptoms and an immune response that contains
the bacilli. In 10% of infected individuals, symptoms develop and
most commonly manifest as pulmonary disease, which accounts
for 80% of all forms of TB disease [1]. TBM develops in around
1% of all cases of active TB [1] and is the most severe form with
mortality rates of 20–25% and high rates of neurological sequelae
in many of those who survive [2,3]. Although only 10% of
individuals who are infected with Mtb develop active disease, it is
not known which immune responses are associated with
susceptibility or resistance. In addition, it is not known why some
individuals have disseminated TB that spreads to the meninges
and central nervous system, while most people have localized
disease in the lungs. Although environmental exposures, pathogen
virulence traits, and host genetics have the potential to influence
the different clinical manifestations of TB, it is not currently
understood which factors are the most important [4].
Several lines of evidence, including twin and genome-wide
linkage studies, suggest that host genetics strongly influences
susceptibility to TB [5–9]. Candidate gene association studies have
implicated common polymorphisms in genes that may influence
the development of TB [10,11]. Although there is potential for
candidate gene study designs to be successful when sample sizes
are sufficient and case and control groups are accurately defined,
candidate genes are usually selected from lists of genes with known
functions. A fundamental problem with this strategy is an inherent
selection bias dominated by well-characterized genes. Further-
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from in vivo murine studies. Although mouse studies have provided
powerful methods to dissect TB immunopathogenesis, the murine
system models primary, progressive disease, which is only one of
several phenotypes observed in humans. There are no well-
established murine models of latent infection or the various types
of disseminated disease, including TBM. Mtb intrathecal infection
of rabbits recapitulates some of the inflammatory pathology but
does not provide insight into the steps in immunopathogenesis
involved in dissemination and invasion of the central nervous
system [12]. To identify genes involved in TBM pathogenesis and
to avoid gene selection bias, we chose to directly examine humans
with different clinical types of TB with an array-based method to
identify candidate genes.
Macrophages mediate the host innate immune response to Mtb
through pathogen recognition and activation of an inflammatory
response. Mtb resides in the macrophage phagolysosome, where it
evades the immune response in the majority of infected
individuals. Successful containment of Mtb replication results in
LTB with no clinical symptoms, which depends on stimulation of
innate and adaptive immune responses that lead to macrophage
activation, formation of granulomas and elimination of the bacilli.
In contrast, failure to contain bacilli replication is associated with
active pulmonary disease and/or the development of disseminated
disease. We hypothesized that different macrophage responses to
Mtb are associated with distinct clinical outcomes that are
genetically regulated.
Expression microarrays have been previously used to examine
gene expression profiles in the immune response to TB [13–17].
None of these studies attempted to distinguish different clinical
forms of active TB such as pulmonary and meningeal disease. In
addition, the sample sizes were generally small and the findings
were often not validated in independent sample sets. Finally, these
previous approaches were not coupled with human genetic studies
to examine the clinical significance associated with variation in the
identified genes. In this manuscript, we examined ex vivo Mtb-
stimulated monocyte-derived macrophages (MDMs) from subjects
with pulmonary, meningeal and latent infection. We attempted to
find unique gene expression profiles to determine whether clinical
phenotypes in TB are associated with distinct early macrophage
responses to Mtb stimulation. We then used a case-control genetic
association study to examine whether genetic variation of these
selected genes was associated with susceptibility to Mtb.
Materials and Methods
Human subjects
TBM subjects were recruited as part of a larger clinical study at
the Hospital for Tropical Diseases, in Ho Chi Minh City (HCMC),
Vietnam [18]. All subjects were .14 years of age and HIV-negative.
TBM patients were described as having clinical meningitis (defined
as nuchal rigidity and abnormal cerebrospinal fluid parameters) in
addition to having a positive Ziehl-Neelsen stain for acid-fast bacilli
and/or Mtb cultured from the cerebrospinal fluid. Subjects were
treated for TBM and were clinically well (recovered for .3 years)
when samples for this study were taken. For PTB subjects, samples
were taken from individuals who had been previously treated and
had recovered from uncomplicated PTB (no evidence of miliary or
extrapulmonary TB). LTB subjects were defined as highly exposed
individuals who had no history of active TB disease. LTB subjects
were healthy nursing staff members who had worked at Pham Ngoc
Thach Hospital for Tuberculosis and Lung Disease, HCMC,
Vietnam for more than 20 years. They were tested for Mtb exposure
using an ESAT-6 and CFP-10- specific IFN-c ELISPOT assay using
a previously described method [19].
For the initial microarray study, twelve subjects were enrolled
with three clinical forms of TB; TBM (n=4), PTB (n=4) and LTB
(n=4). All of the LTB subjects tested positive in the ESAT-6 and/
or CFP-10- specific IFN-c ELISPOT assay, suggesting previous or
current infection with Mtb. An extended sample set containing 34
subjects with TBM (n=10), PTB (n=12) and LTB (n=12) was
used in validation experiments. Of the 12 LTB subjects, 10 were
IFN-c ELISPOT positive according to our defined cut-off [at least
10 spot forming units (SFU) more than the negative PBS control
and at least twice as many SFU as the negative PBS control]. The
2 IFN-c ELISPOT indeterminate LTB subjects had borderline
responses (6.7 SFU with a ratio of 2 and 6 SFU with a ratio of 2.5)
which were considerably higher than an unexposed population
(average of 22.8 SFU with a ratio of 0.8).
For the case-control genetic association study the cohort of
TBM (N=114) and PTB (N=159) patients, and population
controls (cord blood; N=188) has been previously described [20].
All samples came from unrelated individuals who were ethnic
Vietnamese Kinh, as assessed by questionnaire. Written informed
consent was obtained from each patient. Protocols were approved by
human subjects review committees at the Hospital for Tropical
Diseases and Pham Ngoc Thach Hospital for Tuberculosis and Lung
Disease, Ho Chi Minh City, Vietnam. Ethical approval was also
granted by the Oxford Tropical Research Ethics Committee, UK
(OXTREC), The University of Washington Human Subjects
Committee (USA) and the Western Institutional Review Board
(USA).
Ex vivo generation and stimulation of MDMs
Peripheral blood mononuclear cells (PBMCs) were separated
from heparinized whole blood by Lymphoprep (Asix-Shield,
Norway) gradient centrifugation according to the manufacturer’s
protocol. From 20 ml of blood we obtained approximately 1–
1.5610
7 PBMCs. To derive monocytes, PBMCs were plated in
Nunclon Suface 6-well plates (Nunc, Denmark) containing RPMI-
1640 (Sigma, Germany) with 10% heat-inactivated fetal calf serum
Author Summary
Although TB is a leading cause of death worldwide, the
vast majority of infected individuals are asymptomatic and
contains the bacillus in a latent form. Among those with
active disease, 80% have localized pulmonary disease and
20% have disseminated forms. TB meningitis (TBM) is the
most severe form of TB with 20–25% of sufferers dying,
and of the survivors, many have disability. We currently do
not understand the host factors that regulate this diverse
spectrum of clinical outcomes. We hypothesized that
variation in innate immune gene function is an important
regulator of TB clinical outcomes. We measured the mRNA
expression levels of .38,500 genes in macrophages taken
from people with a history of latent, pulmonary, or
meningeal TB and found genes with unique activation
patterns among the clinical groups. Furthermore, we
studied one of these genes further and found that CCL1
polymorphisms were associated with pulmonary TB (PTB)
but not other types of TB disease. To our knowledge, this is
the first study to combine mRNA expression studies with
genetic studies to discover a novel gene that is associated
with different clinical outcomes in TB. We speculate that
this approach can be used to discover novel strategies for
modulating immune function to prevent adverse out-
comes in TB.
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penicillin for 2 hours at 37uC. Non-adhered cells were removed by
washing with phosphate buffered saline (PBS) containing 3% FCS
and adhered cells were incubated for 5 days at 37uC, 5% CO2 to
obtain MDMs. Cells were subsequently stimulated with PBS or
5 mg/ml of an irradiated, soluble, whole cell lysate of Mtb H37Rv
[obtained from the Mycobacteria Research laboratories at Color-
ado State University, USA (http://www.cvmbs.colostate.edu/
microbiology/tb/top.htm)] for 4 hours before RNA extraction.
Pilot studies indicated that 5 mg/ml was an optimal dose for
stimulating TNF-a production.
RNA preparation and microarray hybridization
RNA was extracted from macrophages using Trizol according
to the manufacturer’s protocol (Invitrogen, USA), dissolved in
RNase-free water and stored at 270uC until use. Total RNA
(100 ng) was reverse transcribed to cDNA, amplified, labeled, and
hybridized to the Human Genome U133 Plus 2.0 Array
(Affymetrix, USA), according to the manufacturer’s instructions.
This array contains probe sets to measure the expression level of
47,000 transcripts, including 38,500 well-characterized human
genes. Twelve Mtb-stimulated (TBM n=4, PTB n=4, and LTB
n=4) and 12 PBS-stimulated (hereafter called unstimulated)
samples were hybridized to the array. The microarray data is
publicly available at ArrayExpress, EMBL-EBI (Submission in
progress, awaiting Accession number; http://www.ebi.ac.uk/
microarray-as/aer/?#ae-main[0]).
Microarray data processing and statistics
After normalization of the expression values, the data from 12
Mtb-stimulated samples were compared with the 12 unstimulated
samples. Data were considered significant when (1) the false
discovery rate (FDR) from the Significance Analysis of Microarray
(SAM) analysis for the comparison of stimulated and unstimulated
expression values was ,0.05, and (2) the P value of the
comparison between stimulated versus unstimulated expression
values by Student’s t-test was ,0.05. In order to focus on highly
regulated genes, we also restricted the majority of the analysis to
genes with changes in expression levels of at least 2-fold. To
compare gene expression levels among the three different clinical
types of TB, we first calculated the fold stimulation of each gene
for each individual by dividing the Mtb–stimulated value by the
unstimulated control values. The averages of the 4 samples in each
clinical group were calculated and then compared to the other
groups by calculating the ratios of expression levels. The pair-wise
comparisons included TBM vs. PTB, TBM vs. LTB, and PTB vs.
LTB. SAM [20] was used to derive the FDR for microarray data,
which is the proportion of genes likely to have been identified as
significant by chance. Student’s t-test and analysis of variance
(ANOVA) were used to compare mean expression levels. To
analyze expression patterns in multiple genes simultaneously we
used Hierarchical Clustering [21]. Analyses were performed using
MultiExperiment Viewer (MeV version 4.0, USA) [22] and SPSS
(version 14.0, USA).
Real-time quantitative PCR
Taqman real time PCR was used to validate microarray gene
expression results. cDNA was synthesized from total RNA samples
using reverse transcription with Superscript II following the
manufacturer’s protocol (Invitrogen, USA). A commercial Low
Density Array (LDA) format with Taqman probes and primers
was then used for PCR validation (Applied Biosystems, USA).
Expression levels in 88 genes [86 selected genes and 2 controls
(GAPDH; Hs00237184_m1 and Hs00266705_g1)] were exam-
ined in each sample according to the manufacturer’s instructions.
CCL1 gene expressions on human and mice were examined by
using Taqman probes and primers (Applied Biosystems, USA).
Samples were normalized to GAPDH and analyzed by using
either Applied Biosystems SDS 2.1 Relative Quantification
software or an Excel spreadsheet to perform relative quantification
analysis.
CCL1 chemokine assay
PBMC were isolated from whole blood and cytokine assays
were prepared by plating 10
5 cell per well with RPMI (Life
Technologies) in a 96-well dish, stimulating for 24 hours, and then
harvesting supernatants. Stimuli included: Ultrapure lipopolysa-
charide (LPS) at 100 ng/ml, from Salmonella minnesota R595 (List
Biological Labs, Inc.), Mtb H37Rv whole cell lysate, Mtb H37Rv
cell wall fraction and Mtb H37Rv cytosol fraction (TB Vaccine
Testing and Research Materials Program at Colorado State
University). Chemokine levels were determined with a sandwich
ELISA technique (Duoset, R&D Systems, Minneapolis, MN).
Case-control genetic association study and statistics
SNPs in the CCL1 and CCR8 genes were genotyped in patients
with TBM (N=114), PTB (N=159), and in Vietnamese Kinh
population controls (N=188). This genotyping was performed as
part of a larger genome-wide genetic association study of TB using
the Affymetrix 250K NspI Chip (unpublished). The whole genome
SNP genotyping was performed according to the manufacturer’s
specifications and the data obtained was analyzed following
rigorous quality control. Briefly, data quality control was
performed using DM, BRLMM, RELPAIR, and manual viewing
of cluster plots prior to statistical analysis. STRUCTURE and
Eigentstrat were also used to analyse the population structure of
the sample set. Genomic DNA quality was first assessed with 50
control SNPs and only samples with a call rate of greater than
93% were studied further. For each polymorphism in the full
dataset, filter criteria were applied that included ,5% missing
values and HWE P value.10
25. Power for this study was
calculated by using Power Calculator for Genetic Studies, CaTS
version 0.0.2 (http://www.sph.umich.edu/csg/abecasis/CaTS).
With a sample size of controls=188 and PTB=159 we have
82% power to detect an effect with an odds ratio of 2 for SNPs
with an allele frequency of 10% and significance level of 0.01.
With a sample size of controls=188 and TBM=114, we have a
power of 71% to detect the same effects.
Genotyping was also carried out on selected CCL1 SNPs using
a larger sample set TBM (N=162), PTB (N=175), and in
Vietnamese Kinh population controls (N=380). This was
performed by a MassARRAY
TM technique (Sequenom, San
Diego, USA) using a chip-based matrix-assisted laser desorption/
ionization time-of-flight mass spectrometer as previously described
[18]. All of the CCL1 SNPs genotyped by Sequenom were in
Hardy Weinberg Equilibrium (HWE) (P.0.05) in population
controls.
Univariate analysis was performed for categorical variables with
a Chi-Square test. Two-sided testing was used to evaluate
statistical significance.
Results
Gene expression profiles in Mtb-stimulated and
unstimulated MDMs
We hypothesized that macrophages from individuals with
different TB clinical phenotypes have distinct gene expression
profiles in response to Mtb stimulation. All subjects with
Macrophage Gene Profiles in TB
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of symptoms at the time of venipuncture. Gene expression of
MDMs from subjects with three clinical forms of TB including
LTB, PTB, and TBM (n=4 in each group) was examined by
microarray. MDMs were stimulated either with a whole cell lysate
of Mtb H37Rv or PBS for 4 hours. RNA expression was analyzed
using a Human Genome U133 Plus 2.0 Array (Affymetrix, USA)
which contains probe sets for 47,000 transcripts including 38,500
well-characterized human genes. We compared RNA transcrip-
tion levels in Mtb-stimulated (n=12) versus PBS-stimulated
(n=12) MDMs. 1,608 genes with a FDR of ,5% and a P value
of ,0.05 by Students’s t-test were differentially expressed by
greater than 2-fold (Table 1). Of these genes, 1,260 were up-
regulated and 348 genes were down-regulated. A list of the 1,608
genes that were differentially expressed in the two groups (n=24)
with their mean expression intensities, FDR and P values are
presented in Table S1. 74 genes were up-regulated more than 10-
fold, whereas only one gene was down-regulated by greater than
10-fold (Table 1). We used PANTHER (Protein Analysis Through
Evolutionary Relationships; http://www.pantherdb.org/) to ana-
lyze the molecular functions and biological processes of genes
induced and repressed in Mtb-stimulated MDMs. The changes in
gene expression induced after stimulation contained 144 (8.4%)
immunity and defense genes, including cytokines, chemokines, and
receptors. Thirty six of these genes (25%) were up-regulated more
than 10-fold. In contrast, no immunity and defense genes were
repressed more than 10-fold. Other categories included; develop-
ment (6.7%), protein and nucleic metabolism (19.2%) and signal
transduction (11.9%). By comparison to the entire human genome,
the proportion of immunity and defense genes is 5.2%.
Percentages of other categories include: development (8.5%),
protein and nucleic metabolism (25.1%) and signal transduction
(13.4%).
Gene expression in different clinical phenotypes of TB
(TBM, PTB, LTB)
To examine whether individuals with different clinical forms of
TB have distinct gene expression profiles, we calculated the fold
stimulation of each gene for each individual (dividing Mtb
stimulated value by the unstimulated value) and then calculated
the ratios of gene expression levels in each pair of TB forms. Six
pair-wise comparisons in Table 1 show the change of gene
expression between disease types (in fold change). 33 genes were
differentially expressed between disease types with a ratio .10 and
228 genes had a ratio from 5 to 10.
In Table 2, half of the genes with a ratio .10 (16/33) were
immunity genes including chemokines, cytokines and immune
receptors. Others such as MMP1 and HAS1 are involved in
degrading the extracellular matrix [23]. When all 3 clinical groups
were compared, 16 genes had expression values that were
significantly different (CXCL5, EREG, TNIP3, INHBA, HAS1,
MGC10744, CCL1, KCNJ5, SERPINB7, HS3ST2, APO-
BEC3A, MYO10, SLC39A8, CXCL11, F3, and DUSP5,
ANOVA ,0.05). We then compared expression values of pairs
of clinical groups. There were 11 genes highly expressed in TBM
in comparison to other forms of TB (Table 2). 6/11 genes (IL1B,
CXCL5, EREG, TNIP3, CCR2, and INHBA) were significantly
induced in TBM in comparison to PTB (t test, P,0.05), and all are
genes related to immune function. 5/11 genes were highly
expressed in TBM in comparison to LTB (IL12B, PTGS2,
MMP1, IL23A, and CCL20) however this did not reach statistical
significance due to a consistent outlier in the LTB group (L2 which
does not cluster with the other samples; see below). Twelve genes
were highly expressed in PTB in comparison to LTB and TBM
(PTB/LTB; MMP1, IL23A, HAS1, PTGS2, MGC10744,
CCL20, CCL1, and IL12B, PTB/TBM; HAS1, KCNJ5,
SERPINB7, and HS3ST2). 6/12 had significantly different
expression levels (t test, P,0.05; Table 2). Nine genes were
induced in LTB more than in other TB and 7 of these reached
statistical significance (LTB/TBM; APOBEC3A, LTB/PTB
P2RY13, MYO10, SLC39A8, CXCL11, F3, APOBEC3A,
DUSP5). Together these results suggest that gene expression
profiles in Mtb-stimulated macrophages may distinguish between
the 3 different clinical forms of TB, LTB, PTB, and TBM.
Validation results
We used real-time PCR using a TaqMan Low Density Array
technique to confirm microarray results in 86 genes in an extended
sample set which included 12 LTB, 12 PTB, and 10 TBM
individuals. Fifty-eight of the 86 genes were selected from the
microarray data based on high levels of induction (.15 fold) or
repression (.5 fold) following Mtb stimulation. Forty six genes
were selected based on array expression differences among the 3
clinical groups (.5 fold). We first assessed whether the expression
patterns of the 58 up and down-regulated genes were replicated in
the independent sample set using RT-PCR. In total, 90% (52/58)
of the microarray results were confirmed by RT-PCR when
assessing Mtb and PBS-stimulated expression values in the
validation sample set (Table 3 and Table S2). The RT-PCR
results showed that 5/58 genes (IFIT1, CXCL6, MERTK, CD36,
and MS4A6A) were not significantly induced or repressed by Mtb
stimulation (n=34; P.0.05 by t-test) and the expression pattern of
one gene, CCR2, was reversed (Table 3). In addition, the majority
of the genes in the validation group (n=34) had a higher induction
level in comparison to the microarray group (n=12; Table 3).
We next compared gene expression levels in the 3 clinical
groups in the validation sample set. The RT-PCR results showed
that 2/46 genes (CCL1 and HS3ST3B1) were differentially
Table 1. Gene expression ratios in Mtb stimulated MDMs.
ratio.10 5,ratio,10 2,ratio,5
(# genes) (# genes) (# genes)
All TB
a
Up regulated 74 111 1,075
Down regulated 1 13 334
Total 75 124 1,409
TB clinical phenotypes
b
TBM/PTB 6 27 450
PTB/TBM 4 14 500
TBM/LTB 5 55 1,763
LTB/TBM 2 35 1,474
PTB/LTB 8 46 1,688
LTB/PTB 8 51 1,519
Total 33 228 7,394
aAll TB; the ratio indicates the mean of Mtb stimulated samples (n=12) divided
by the mean of PBS-stimulated samples (n=12) when analyzed with the U133
Plus 2.0 Array.
bTB clinical phenotypes; six pairwise comparisons were derived between 2
clinical phenotypes of either TBM, PTB, or LTB. Ratios derived by first dividing
the mean value of Mtb stimulated samples (n=4) by the PBS-stimulated
samples (n=4) in each group and then calculating ratios of expression levels
between two groups.
doi:10.1371/journal.ppat.1000229.t001
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test; Table 4). CCL1 was up-regulated in PTB when compared to
LTB in both the RT-PCR LDA validation samples (P=0.02 by t-
test; 1.9-fold) and the initial microarray analysis (12.8-fold; Table 4
and Table S3). HS3ST3B1 was down regulated in LTB when
compared to TBM in the RT-PCR LDA validation samples
(P=0.008 by t-test; ratio=0.4) but this pattern of expression was
reversed in the initial microarray analysis (ratio=12.8) (Table 4).
Scatter plots of CCL1 and HS3ST3B1 are shown in Figure 1
along with 3 other representative genes. Seven other genes
(INHBA, TSLP, LY6K, IL12B, MMP1, CCL20 and HAS1) had a
greater than 2-fold change in expression ratios of the validation
Table 2. Thirty-three genes with altered expression ratios among different clinical forms of TB.
Gene Symbol Characteristic Means Ratio t-test
a ANOVA
b
TBM/PTB LTB PTB TBM TBM/PTB P value p value
IL1B immune cytokine 71.7 28.5 440.9 15.5 0.013 0.074
CXCL5 immune chemokine 3.0 1.4 18.6 13.7 0.006 0.016
EREG immune signaling 70.5 25.0 331.5 13.3 0.001 0.024
TNIP3 immune signaling 39.6 10.5 131.9 12.5 0.002 0.002
IL1B immune cytokine 51.7 26.5 285.2 10.8 0.013 0.095
CCR2 immune chemokine 0.2 0.1 0.7 10.6 0.026 0.133
INHBA immune signaling 50.2 8.4 86.4 10.3 ,0.001 0.039
TBM/LTB TBM/LTB
IL12B immune cytokine 0.8 1.7 97.0 123.9 0.074 0.083
PTGS2 immune signaling 11.6 3131.3 1027.4 88.5 0.184 0.236
MMP1 extracellular matrix 0.1 16.3 3.8 59.4 0.247 0.115
IL23A immune cytokine 0.2 1.2 9.2 42.9 0.184 0.110
CCL20 immune chemokine 22.1 319.4 393.8 17.9 0.824 0.952
PTB/LTB PTB/LTB
MMP1 extracellular matrix 0.1 16.3 3.8 256.7 0.088 0.115
IL23A immune cytokine 0.2 16.8 9.2 78.5 0.099 0.110
HAS1 extracellular matrix 1.9 73.3 1.6 39.5 0.007 0.001
PTGS2 immune signaling 11.6 248.2 1027.4 21.4 0.559 0.236
MGC10744 hypothetical protein 1.4 23.4 2.3 16.3 ,0.001 ,0.001
CCL20 immune chemokine 22.1 319.4 393.8 14.5 0.830 0.952
CCL1 immune chemokine 1.5 18.8 3.2 12.8 0.004 0.004
IL12B immune cytokine 0.8 9.8 97.0 12.5 0.481 0.083
PTB/TBM PTB/TBM
HAS1 extracellular matrix 1.9 73.3 1.6 47.2 0.005 0.001
KCNJ5 immune receptor 0.1 0.7 0.0 42.2 ,0.001 0.001
SERPINB7 serine proteinase inhibitor 1.7 21.9 1.0 21.5 0.025 0.016
HS3ST2 transferase activity 0.5 1.0 0.1 11.1 ,0.001 0.005
LTB/TBM LTB/TBM
APOBEC3A hydrolase activity 33.3 2.8 1.5 22.0 0.041 0.024
HS3ST3B1 non immu signaling 26.8 6.4 2.2 12.0 0.090 0.100
LTB/PTB LTB/PTB
P2RY13 purinergic receptor 1.0 0.0 0.1 27.1 0.018 0.067
LOC348938 hypothetical protein 17.1 0.9 10.0 18.7 0.123 0.158
MYO10 myosin X 39.1 2.5 6.1 15.8 0.003 0.002
SLC39A8 solute carrier 43.7 3.0 16.7 14.6 0.001 0.001
CXCL11 immune chemokine 78.0 6.0 36.7 13.1 0.003 0.002
F3 coagulation factor 191.1 15.6 114.6 12.3 0.011 0.011
APOBEC3A hydrolase activity 33.3 2.8 1.5 12.0 0.024 0.024
DUSP5 phosphatase 37.2 3.5 7.7 10.7 0.005 0.016
at-test was used to compare means between the 2 indicated clinical groups.
bANOVA was used to compare means among the 3 clinical groups.
P values,0.05 in bold.
doi:10.1371/journal.ppat.1000229.t002
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Up-regulated genes Gene Microarrays
aFDR
cLDA t-test Gene description
Gene function
bratio %
bratio P value
Immunology
Chemokines CCL20 29.7 0.0E+00 682.7 2.31E-19 C-C motif, ligand 20
CXCL1 27.9 0.0E+00 181.4 1.39E-03 C-X-C motif, ligand 1
CXCL11 21.6 0.0E+00 127.4 1.86E-11 C-X-C motif, ligand 11
CXCL6 19.9 0.0E+00 670.8 0.065 C-X-C motif, ligand 6 (granulocyte chemotactic protein 2)
CCL3 12.8 0.0E+00 26.8 3.23E-10 C-C motif, ligand 3
GPR109B 9.6 0.0E+00 12.7 7.48E-07 chemokine receptor, G protein-coupled receptor 109B
CXCL10 3.6 3.0E-01 24.1 8.83E-06 C-X-C motif, ligand 10
Cytokines IL1A 101.3 0.0E+00 1468.2 5.05E-40 interleukin 1, alpha
IL6 101.3 0.0E+00 853.1 1.55E-33 interleukin 6 (interferon, beta 2)
IL1B 34.0 0.0E+00 688.6 2.78E-24 interleukin 1, beta
CCL4 33.3 0.0E+00 1911.6 1.93E-09 C-C motif, ligand 4
CXCL3 19.2 0.0E+00 156.6 5.74E-13 C-X-C motif, ligand 3
IL10 12.3 0.0E+00 6.1 9.75E-04 interleukin 10
IL1F9 12.0 0.0E+00 100.4 5.61E-10 interleukin 1 family, member 9
CXCL2 11.5 0.0E+00 19.3 3.66E-08 C-X-C motif, ligand 2
PBEF1 9.7 0.0E+00 15.4 1.20E-07 Pre-B-cell colony enhancing factor 1
IL12B 6.5 0.0E+00 3350.8 2.78E-24 interleukin 12B
CCL8 5.8 0.0E+00 33.8 9.59E-08 C-C motif, ligand 8
Receptors CD80 12.6 0.0E+00 10.2 9.76E-07 CD80 antigen (CD28 antigen ligand 1, B7-1 antigen)
TNFRSF4 6.0 0.0E+00 8.4 8.73E-08 tumor necrosis factor receptor superfamily, member 4
Signaling PTX3 56.0 0.0E+00 182.2 5.06E-17 pentaxin-related gene, rapidly induced by IL-1 beta
EREG 44.3 0.0E+00 61.7 1.83E-13 epidermal growth factor family
PTGS2 26.8 0.0E+00 351.3 8.86E-16 prostaglandin-endoperoxide synthase 2
TNFAIP6 24.2 0.0E+00 284.2 1.11E-17 tumor necrosis factor, alpha-induced protein 6
IFIT1 22.2 0.0E+00 24.9 0.903 interferon-induced protein with tetratricopeptide repeats 1
IRAK2 16.0 0.0E+00 6.7 1.54E-05 interleukin-1 receptor-associated kinase 2
TNIP3 14.6 0.0E+00 11294.5 1.12E-14 TNFAIP3 interacting protein 3
TRAF1 14.4 0.0E+00 11.5 1.34E-07 TNF receptor-associated factor 1
INHBA 13.1 0.0E+00 88.9 4.19E-09 TGF-beta superfamily members
IFIT2 10.3 0.0E+00 86.1 8.27E-04 interferon-induced protein with tetratricopeptide repeats 2
IFIT3 9.0 0.0E+00 49.6 1.24E-09 interferon-induced protein with tetratricopeptide repeats 3
Not immunology
Receptors CD44 8.0 0.0E+00 2.6 1.43E-02 CD44 antigen
Signaling JAG1 11.0 0.0E+00 13.1 3.02E-07 jagged 1 (Alagille syndrome)
INSIG1 8.7 0.0E+00 19.5 1.03E-07 insulin induced gene 1
Matrix PLAUR 9.0 0.0E+00 9.8 1.02E-06 plasminogen activator, urokinase receptor
THBS1 6.5 0.0E+00 3.2 1.75E-02 thrombospondin 1
MMP19 5.7 0.0E+00 13.6 8.35E-07 extracellular matrix
Other SOD2 30.5 0.0E+00 7.5 1.81E-03 superoxide dismutase 2, mitochondrial
F3 27.0 0.0E+00 7.0 3.58E-06 coagulation factor III (thromboplastin, tissue factor)
SERPINB2 19.6 0.0E+00 57.5 4.78E-06 serine proteinase inhibitor, member 2
G0S2 17.5 0.0E+00 81.1 1.63E-13 putative lymphocyte G0/G1 switch gene
HEY1 17.3 0.0E+00 49.3 3.32E-10 hairy/enhancer-of-split related with YRPW motif 1
PHLDA2 15.6 0.0E+00 12.3 1.17E-03 pleckstrin homology-like domain, family A, member 2
SGPP2 14.3 0.0E+00 15.9 4.36E-09 Sphingosine-1-phosphate phosphotase 2
OASL 12.7 0.0E+00 39.5 2.35E-12 29-59-oligoadenylate synthetase-like
MET 9.0 0.0E+00 33.0 8.68E-08 met proto-oncogene (hepatocyte growth factor receptor)
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not reach statistical significance (P.0.05; Table 4). These results
suggest that the different TB clinical phenotypes cannot easily be
distinguished by examining expression levels of single genes.
Cluster analysis of the 3 clinical phenotypes
We next hypothesized that expression profiles from multiple
genes would need to be combined to detect patterns that could
distinguish the different clinical disease phenotypes. We selected
1,608 highly induced or repressed genes from the microarray data
set (Table S1) and used an unsupervised, hierarchical clustering
algorithm [21] of 12 individual samples to attempt to distinguish the
profiles of the 3 groups (Figure S1). These results showthat, (1)there
was more relatedness between expression levels of samples from the
same clinical group, i.e. L1 and L3 are very similar, P1, P2 and P3
are very similar, and M1 and M4 are very similar, and (2) one large
cluster containing data from all TBM subjects, all PTB subjects and
one LTB subject (L4) is very distinct to data from subjects L2, L1
and L3. Together, these findings suggest that cluster analysis can
partially distinguish different clinical forms of TB.
CCL1 SNPs are associated with TB
CCL1 was the only gene whose expression was up-regulated in
both the microarray and validation data sets when comparing
clinical forms of TB (PTB vs LTB). We next examined whether
genetic variants of CCL1 were associated with susceptibility to TB
in a case-control study with TBM (N=114) and PTB patients
(N=159), and population controls (N=188) by using gene chip
mapping assays. Forty nine SNPs were genotyped across a 200 kb
region of the chromosome 17 CCL gene family cluster. Eight of
the forty nine SNPs were associated with TB. To further locate the
region associated with TB, we arbitrarily divided the whole region
into four 50 kb sections. The first section containing CCL2 had 1/
9 associated SNPs, the second containing CCL7 and CCL11 had
1/9 associated SNPs, the third containing CCL8 and CCL13 had
1/7 associated SNPs and the fourth containing CCL1 had 4/23
associated SNPs (Figure 2). To investigate this further we
genotyped 10 SNPs nearby and in the coding region of CCL1
using Sequenom. Two more SNPs in the CCL1 gene were
significantly associated with TB by genotypic comparison (Table 5).
Together these results suggest that polymorphisms near and within
the CCL1 genomic region are associated with susceptibility to
different TB phenotypes.
Regulation of CCL1 Expression
To further investigate the role of CCL1 in Mtb pathogenesis, we
examined regulation of its expression. We found that CCL1 mRNA
expression was cell-specific and highly induced in monocytic (THP-1,
U937, & PBMCs) cells stimulated with Mtb lysates or TLR ligands
(LPS, PAM2, PAM3) (Figure 3A). In contrast, no expression was
found in epithelial cell lines (HeLa & A549, data not shown). We also
found that CCL1 protein secretion was induced in THP1 cells and
PBMCs by Mtb, including whole cell lysates, cell wall and cytosolic
fractions [Figure 3B and data not shown; PBS vs TB whole cell lysate
(TBWCL; P=0.01), PBS vs TB cell wall (TBCW; P=0.006) and
PBS vs TB cytosol (P=0.02)]. Finally, we examined CCL1
expression in murine bone-marrow derived macrophages stimulated
with PBS, LPS or Mtb from wild-type (WT) and Myd882/2 mice.
CCL1 expression was highly induced by LPS and Mtb in WT bone
marrow macrophages (BMMs). However, CCL1 expression was
decreased in MyD88-deficient BMMs stimulated with LPS (P=0.03)
or Mtb (P=0.002) (Figure 3C). Together, these results suggested that
CCL1 expression is highly enriched in monocytes and induced by
Mtb components in a MyD88-dependent manner.
Discussion
In this study we examined macrophage transcriptional profiles
in individuals with different clinical forms of TB. The majority of
reported TB microarray studies have examined healthy donors,
Up-regulated genes Gene Microarrays
aFDR
cLDA t-test Gene description
Gene function
bratio %
bratio P value
FNDC3B 8.2 0.0E+00 3.5 2.36E-03 fibronectin type III domain containing 3B
IFI44L 6.0 0.0E+00 11.3 1.49E-04 interferon-induced protein 44-like
Down-regulated genes
Immunology
Chemokines CCR2 0.2 4.1E+00 6.2 3.93E-04 C-C motif, receptor 2
Signaling BIRC1 0.1 0.0E+00 0.2 1.1103E-18 baculoviral IAP repeat-containing 1
GLUL 0.2 4.4E-01 0.3 2.50E-02 glutamate-ammonia ligase (glutamine synthase)
MERTK 0.2 9.1E-02 0.4 0.090 c-mer proto-oncogene tyrosine kinase
Receptor KCNJ5 0.1 5.9E-01 0.1 1.04E-03 Potassium inwardly-rectifying channel, member 5
Other P2RY13 0.2 1.3E+00 0.3 7.67E-04 purinergic receptor P2Y, G-protein coupled, 13
DAB2 0.2 1.1E+00 0.2 3.41E-03 disabled homolog 2, mitogen-responsive phosphoprotein
CD36 0.3 3.0E+00 0.6 0.505 CD36 antigen (collagen type I receptor)
MS4A6A 0.3 0.0E+00 0.6 0.551 membrane-spanning 4-domains, subfamily A, member 6A
STAC 0.5 8.4E+00 0.5 1.44E-02 SH3 and cysteine rich domain
aFDR=false discovery rate of microarrays using SAM.
bratio indicates the mean of Mtb stimulated samples divided by the mean of PBS stimulated samples with data derived from microarray (n=12) or.
cLDA real-time PCR (n=34).
doi:10.1371/journal.ppat.1000229.t003
Table 3. cont.
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aComparison
aComparison Gene function
Microarray LDA t-test
Gene name TBM/PTB TBM/PTB P value
INHBA 15.5 2.8 0.347 immune signaling
IL1B 15.5 1.0 0.901 immune cytokine
TNIP3 12.5 0.1 0.354 immune signaling
CCR2 10.6 1.2 0.596 immune chemokine
CTHRC1 9.5 0.6 0.585 extracellular matrix
STAC 7.9 1.8 0.254 metal ion binding
TSLP 6.8 2.8 0.266 immune cytokine
SLC16A10 6.5 0.8 0.322 menbrane transporter
CXCL11 6.2 1.8 0.369 immune chemokine
CHIT1 5.8 0.8 0.342 chitotriosidase
LY6K 5.8 6.4 0.269 immune receptor
PBEF1 5.5 1.4 0.413 immunity and defense
CXCL12 6.2 0.6 0.354 immune chemokine
UBE3A 8.0 1.1 0.660 ligase activity
CD69 8.2 1.1 0.737 immune receptor
SF1 8.0 1.6 0.219 RNA splicing
CNR1 7.2 0.5 0.128 neuroactive ligand-receptor
GSTA4 6.2 1.3 0.297 cell growth factor
MT1H 5.9 0.9 0.763 metal ion binding
SLITRK6 5.7 0.0 0.324 protein binding
RGS1 5.7 1.3 0.509 immune signaling
TAOK1 5.3 1.0 0.943 kinase
COCH 7.8 0.7 0.116 coagulation factor
RASGEF1B 8.8 1.4 0.258 guanyl-nucleotide exchange factor
CD36 9.5 1.2 0.446 immune receptor
BCL2L14 6.6 1.1 0.833 protein binding in regulation of apoptosis
GRK5 5.2 1.0 0.811 non immune signaling
TBM/LTB TBM/LTB
IL12B 123.9 3.4 0.511 immune cytokine
MMP1 59.4 3.1 0.775 extracellular matrix
IL23A 42.9 1.8 0.381 immune cytokine
CCL20 17.9 2.5 0.065 immune chemokine, MIP3A
PTB/LTB PTB/LTB
HAS1 39.5 3.7 0.407 extracellular matrix
CCL1 12.8 1.9 0.020 immune chemokine
PTB/TBM PTB/TBM
HS3ST2 11.1 3.0 0.095 transferase activity
LTB/TBM LTB/TBM
HS3ST3B1 12.0 0.4 0.008 non immune signaling
APOBEC3A 22.0 0.4 0.277 hydrolase activity
PSD3 6.1 0.9 0.781 guanyl-nucleotide exchange factor
FCAR 6.4 0.6 0.178 immune receptor
RIN2 6.5 0.7 0.149 guanyl-nucleotide exchange factor
LTB/PTB LTB/PTB
P2RY13 27.1 0.5 0.375 non immune signaling
MMP19 5.5 1.8 0.157 extracellular matrix
AK3 5.7 0.6 0.099 kinase
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compared gene expression profiles of individuals with different
clinical forms of TB [24]. Mistry et al obtained whole blood from
individuals with active, latent, cured (following 1 disease episode)
and recurrent TB (following 2–3 episodes) [24]. Discriminant
analysis suggested that 9 genes could distinguish the 4 clinical TB
groups [24]. We examined these 9 genes in our data set and found
these genes could not differentiate our latent and cured TB groups.
These differences may be attributable to the study design, which
was substantially different from the current investigation with
regard to cell population (whole blood vs MDMs), stimuli (none vs
whole cell Mtb lysate), ethnic background (South African vs
Vietnamese) and comparison of different clinical phenotypes.
Despite these methodologic differences, both studies suggest that
host gene expression profiles uniquely identify groups of
individuals with different types of TB. Our study further illustrates
Figure 2. The CCL gene cluster containing CCL1 on chromosome 17. The black boxes denote the genes that are found in this region and the
TB associated SNPs are approximately located by the dashed lines. *denotes gene encoding a hypothetical protein. Not to scale.
doi:10.1371/journal.ppat.1000229.g002
aComparison
aComparison Gene function
Microarray LDA t-test
Gene name TBM/PTB TBM/PTB P value
CXCL10 6.6 1.3 0.434 immune chemokine
HLA-DOB 7.3 0.8 0.163 immune receptor
CD24 8.1 1.2 0.607 immune receptor
CSF2 9.5 0.2 0.356 immune cytokine
aThe comparison was calculated from ratios of mean values of the Mtb-stimulated samples over PBS-stimulated samples in each clinical group (LTB n=12, PTB n=12,
and TBM n=10). t-test was used to compare means between the 2 indicated clinical groups from the LDA data.
doi:10.1371/journal.ppat.1000229.t004
Table 4. cont.
Figure 1. Scatter plots of gene expression from 3 TB clinical groups. mRNA expression values from the RT-PCR validation step are depicted
from 5 representative genes (n=34). Expression values are ratios of Mtb-stimulated gene expression in comparison to PBS-stimulation in LTB (dark
round), PTB (empty round), and TBM (triangle).
doi:10.1371/journal.ppat.1000229.g001
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SNP, group Position Allele Genotype Allelic comparison
Genotypic
comparison
1 2 1 2 1 11 22 2 O R
a (95%CI
b) P value P value
rs10491110 29572630 T C
Control 296 (0.79) 80 (0.21) 119 (0.63) 58 (0.31) 11 (0.06)
cAll TB 554 (0.84) 104 (0.16) 233 (0.71) 88 (0.27) 8 (0.02) 0.7 (0.5–0.9)
d0.027 0.063
PTB 297 (0.83) 63 (0.18) 122 (0.68) 53 (0.29) 5 (0.03) 0.9 (0.5–1.1) 0.196 0.311
TBM 257 (0.86) 41 (0.14) 111 (0.75) 35 (0.24) 3 (0.02) 0.6 (0.4–0.9) 0.012 0.047
TBM/PTB 0.7 (0.5–1.1) 0.190 0.408
rs3091324 29625029 C A
Control 270 (0.73) 98 (0.27) 101 (0.55) 68 (0.37) 15 (0.08)
All TB 478 (0.73) 178 (0.27) 174 (0.53) 130 (0.40) 24 (0.07) 1.0 (0.7–1.3) 0.862 0.818
PTB 276 (0.77) 84 (0.23) 104 (0.58) 68 (0.38) 8 (0.04) 0.8 (0.6–1.1) 0.304 0.344
TBM 202 (0.68) 94 (0.32) 70 (0.47) 62 (0.42) 16 (0.11) 1.2 (0.9–1.7) 0.147 0.367
*TBM/PTB 1.5 (1.0–2.1) 0.016 0.038
rs2072069 29709104 A G
Control 375 (0.50) 373 (0.50) 91 (0.24) 193 (0.52) 90 (0.24)
All TB 318 (0.48) 338 (0.52) 88 (0.27) 142 (0.43) 98 (0.30) 1.1 (0.9–1.3) 0.535 0.098
PTB 163 (0.47) 183 (0.53) 40 (0.23) 83 (0.48) 50 (0.29) 1.1 (0.9–1.5) 0.352 0.481
TBM 155 (0.50) 155 (0.50) 48 (0.31) 59 (0.38) 48 (0.31) 1.0 (0.8–1.3) 0.968 0.015
*TBM/PTB 0.9 (0.7–1.2) 0.459 0.175
rs159319 29710800 A G
Control 210 (0.56) 166 (0.44) 56 (0.30) 98 (0.52) 34 (0.18)
All TB 332 (0.51) 322 (0.49) 83 (0.30) 166 (0.51) 78 (0.24) 1.2 (1.0–1.6) 0.115 0.256
PTB 170 (0.48) 188 (0.53) 39 (0.22) 92 (0.51) 48 (0.27) 1.4 (1.0–1.8) 0.023 0.067
TBM 162 (0.55) 134 (0.45) 44 (0.30) 74 (0.50) 30 (0.20) 1.0 (0.7–1.4) 0.771 0.869
*TBM/PTB 0.7 (0.5–1.0) 0.065 0.173
rs3138031 29712619 A C
Control intron CCL1 684 (0.95) 38 (0.05) 324 (0.90) 36 (0.10) 1 (0.00)
All TB 481 (0.94) 29 (0.06) 230 (0.90) 21 (0.08) 4 (0.02) 1.1 (0.7–1.8) 0.747 0.174
PTB 240 (0.92) 22 (0.08) 113 (0.86) 14 (0.11) 4 (0.03) 1.7 (1.0–2.8) 0.069 0.024
TBM 241 (0.97) 7 (0.03) 117 (0.94) 7 (0.06) 0 (0.00) 0.5 (0.2–1.2) 0.114 0.145
*TBM/PTB 0.3 (0.1–0.7) 0.006 0.064
rs159290 29725037 T C
Control 212 (0.56) 164 (0.44) 58 (0.31) 96 (0.51) 34 (0.18)
All TB 340 (0.52) 316 (0.48) 85 (0.26) 170 (0.52) 73 (0.22) 1.2 (0.9–1.5) 0.158 0.355
PTB 171 (0.48) 187 (0.52) 38 (0.21) 95 (0.53) 46 (0.26) 1.4 (1.1–1.9) 0.019 0.056
TBM 169 (0.57) 129 (0.43) 47 (0.32) 75 (0.50) 27 (0.18) 1.0 (0.7–1.4) 0.933 0.989
*TBM/PTB 1.4 (1.1–1.8) 0.022 0.062
rs159291 29725240 C T
Control 207 (0.56) 165 (0.44) 55 (0.30) 97 (0.52) 34 (0.18)
All TB 339 (0.52) 319 (0.48) 84 (0.26) 171 (0.52) 74 (0.23) 1.2 (0.9–1.5) 0.202 0.422
PTB 170 (0.47) 190 (0.53) 37 (0.21) 96 (0.53) 47 (0.26) 1.4 (1.1–1.8) 0.023 0.063
TBM 169 (0.57) 129 (0.43) 47 (0.32) 75 (0.50) 27 (0.18) 1.0 (0.7–1.3) 0.782 0.923
*TBM/PTB 0.7 (0.5–0.9) 0.015 0.052
rs159294 29728905 T A
Control 333 (0.89) 43 (0.11) 145 (0.77) 43 (0.23) 0 (0.00)
All TB 534 (0.82) 122 (0.19) 217 (0.66) 100 (0.31) 11 (0.03) 1.8 (1.2–2.6) 0.003 0.004
PTB 286 (0.79) 74 (0.21) 114 (0.63) 58 (0.32) 8 (0.04) 2.0 (1.3–3.0) ,0.001 0.001
TBM 248 (0.84) 48 (0.16) 103 (0.70) 42 (0.28) 3 (0.02) 1.5 (1.0–2.3) 0.070 0.065
*TBM/PTB 0.7 (0.5–1.1) 0.155 0.318
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pathogenesis, are a key source of the unique transcriptional profile
that distinguishes clinical forms of TB.
One limitation of our study was the small sample size. Although
this is the largest number of individuals ever studied in a TB
microarray study, comparable only to the study by Mistry et al
[24], the sample size remains small for this statistically challenging
question. To overcome some of the limitations of a small sample
size for microarrays (n=12), we included an independent set of
samples for validation (n=34). We also chose to use a whole cell
lysate of a standardized Mtb strain rather than live organisms and a
relatively short stimulation time (t=4 hours) to minimize variation
in our stimulation conditions and to enhance the detection of early
innate immune response genes. We examined these cells in an ex
vivo environment to avoid variability that is attributable to complex
in vivo environments. For example, we studied individuals after
they had been treated for TB to avoid detecting gene expression
changes that are attributable to stimulation of in vivo inflammatory
pathways from active disease. We also chose to study macrophages
rather than whole blood in order to concentrate on a single cell
population that is most relevant for Tb pathogenesis. A number of
studies have shown that the strain of Mtb induces different immune
responses [25,26]. Although the choice of Mtb strain could
stimulate different gene expression profiles, we chose to study
the commonly used laboratory strain (Mtb H37Rv). Each of these
experimental conditions was selected to maximize the opportuni-
ties of detecting differences attributable to genetic variation in the
macrophage innate immune response to TB. Comparison of gene
expression results with alternative experimental conditions (such as
different cell types, Mtb strains, Mtb growth conditions, and time
points) could further illuminate the role of these genes in Tb
pathogenesis.
In addition to comparing expression profiles among people with
different types of TB, our study contributes further data on the set
of genes that are activated in response to Mtb stimulation of
macrophages. Our results demonstrated that 1,608 genes in
macrophages were stimulated (up or down-regulated) by Mtb.
Furthermore, 90% of a subset of these genes (n=58 genes induced
.15 fold by Mtb stimulation) in a second round validation also
showed altered expression. Many genes identified in our study
have also been detected in previous studies investigating the host
response to Mtb infection [13,16,17]. Ragno et al studied THP-1
cells stimulated with live TB and measured the expression of 375
genes after 6 or 12 hours of stimulation. Our data confirmed 15
SNP, group Position Allele Genotype Allelic comparison
Genotypic
comparison
1 2 1 2 1 11 22 2 O R
a (95%CI
b) P value P value
rs210837 29759282 C T
Control 331 (0.88) 45 (0.12) 143 (0.76) 45 (0.24) 0 (0.00)
All TB 542 (0.83) 114 (0.17) 219 (0.67) 104 (0.32) 5 (0.02) 1.5 (1.1–2.2) 0.021 0.032
PTB 292 (0.82) 66 (0.18) 117 (0.65) 58 (0.32) 4 (0.02) 1.6 (1.1–2.5) 0.014 0.018
TBM 250 (0.84) 48 (0.16) 102 (0.69) 46 (0.31) 1 (0.01) 1.4 (0.9–2.2) 0.122 0.182
*TBM/PTB 0.8 (0.6–1.3) 0.434 0.477
aFor odds ratio (OR) calculation each group was compared with the control group, except for OR calculation for TBM/PTB, where TBM was compared with PTB.
bCI, confidence inte.
cAll TB represents the combination of PTB and TBM.
dnumbers in bold represent P values,0.05.
doi:10.1371/journal.ppat.1000229.t005
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Figure 3. The cellular function of CCL1. (A) CCL1 mRNA expression in cells stimulated with Mtb and TLR ligands. Real-time PCR quantification of
CCL1 in THP1 (grey columns), U937 (open columns), and PBMC (solid columns). Cells were stimulated with LPS (100 ng/ml), whole cell H37Rv Mtb
lysates (50 mg/ml), and lipopeptides PAM2 or PAM3 (250 ng/ml). Cells were stimulated for 4 hours and mRNA was extracted and measured by real-
time PCR. (B) CCL1 secretion in PBMCs stimulated with Mtb. PBMCs were stimulated with LPS (100 ng/ml), whole cell H37Rv Mtb lysates (50 mg/ml), TB
cell wall (5 mg/ml), or TB cytosol (5 mg/ml). After stimulation for 24 hours, supernatants were assayed for CCL1 production by ELISA. Values represent
mean and standard deviation of triplicate samples. Student’s t-test for comparisons between non-stimulated and either LPS, TBWCL, TBCW, or TB
cytosol have P=0.002, 0.01, 0.006, and 0.02, respectively. (C) CCL1 expression in BMM from Myd882/2 (open columns) and wild-type mice (solid
columns). BMM were stimulated with LPS (100 ng/ml) or Mtb (100 mg/ml) for 4 hours. Means of CCL1 expression examined in triplicate by real-time
PCR are shown.
doi:10.1371/journal.ppat.1000229.g003
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set (MIP-1a, MIP-1b, MIP-3a, MPIF-1, PARC, RANTES, IL-8,
GRO-a, GRP-b, GRO-c, CCL1, CCR3, IL-1b, TNFa, and
VEGF) [17]. Nau et al studied primary human MDMs stimulated
with live Mtb [16]. Eleven genes were highly expressed in both
data sets (TNFAIP6, CXCL3, CXCL1, CCL4, PTGS2, SER-
PINB2, PTX3, INHBA, TRAF1, JAG1, and SOD2) and 3 genes
were inhibited (MERTK, GLUL, and DAB2). These gene lists
include cytokines, chemokines and immune receptors, which may
be involved in inflammatory responses in the early phases of
defense against Mtb. All of the up-regulated genes identified by
Nau et al were found in our dataset [16]. In contrast, only 50%
(24/50) of highly expressed genes in our dataset were identified by
Nau et al, a difference that is likely due to the array sizes that were
utilized (38,000 vs. 980 genes). Although these microarray studies
have important methodologic differences (e.g primary cells vs cell
lines, healthy subjects vs. TB patients, live versus dead Mtb
stimulation, stimulation times, arrays and genes analyzed), all of
these studies have identified novel genes potentially related to the
host macrophage response to Mtb.
Our study compares transcriptional profiles of individuals with
TBM with individuals with other forms of TB. We identified genes
that were distinctly expressed in macrophages from individuals
with a history of TBM. After bacilli invade the host lung within the
pulmonary alveolar macrophage, they replicate and disseminate to
the regional lymph nodes. During this early stage of infection,
before the development of adaptive immunity, the bacteria can
spread haematogenously to other organs in the body and cause
extrapulmonary disease, such as TBM [27,28]. This step may be
determined by the nature and extent of the innate immune
response activated by infected macrophages. We found that
several macrophage immune response genes (IL1B, IL12B, TNF,
TNIP3, CXCL10, CXCL11, CCL12, and CCL1) were up-
regulated in TBM subjects in comparison to those with PTB and
LTB. In addition, some genes, such as MMP1 and HAS1, were
found with differing expression in PTB and TBM patients. These
genes are involved in degrading the extracellular matrix and could
mediate a role in granuloma formation and bacillus containment,
which could influence dissemination and development of TBM
[23]. Although the relationship between the inflammatory
response and TBM pathogenesis is only partially understood,
excessive immune activation may be intimately associated with
disease severity and outcome.
Case-control genetic association studies of biologically plausible
candidate genes have been performed with the hope to identify
genes involved in susceptibility to, and clinical outcome of, TB.
However it has always been challenging to identify potential
candidate genes in an unbiased manner. The expression profiling
study we describe here can serve as a hypothesis generating,
unbiased methodological approach to identify genes for potential
association studies. Despite this advantage, gene regulation is not
the only mechanism for genetic resistance or susceptibility and
non-synonymous coding region SNPs which alter protein structure
and function also play an important role. From the genes that were
differentially expressed between TB disease types, as assessed by
microarray, we tested 46 genes in a separate, larger sample set by
RT-PCR. The expression of only one of these genes, CCL1,
remained significantly different between patients with different
clinical TB outcomes. To test our selection approach we
performed a case-control genetic association study and found that
SNPs near CCL1 were associated with susceptibility to PTB. The
fact that SNPs near CCL1 were significantly associated with PTB
in our study highlights the feasibility of this unbiased selection
approach.
Even though the associated SNPs are not within the CCL1
coding region, it is a likely candidate gene due to it’s proximity to
the cluster of associated SNPs and its functional relevance. CCL1,
like other members of the CC chemokine family, is an
inflammatory mediator that stimulates the migration of human
monocytes [29]. CCL1 is produced by monocytes (as well as other
cells) and binds its receptor CCR8, which is present on
lymphocytes and monocytes [30]. Interestingly, CCR8 has
enriched expression on Th2 and regulatory T cells and may
influence the development of Th2 type T cell responses in vivo
[31,32]. In addition, CCR8 regulates migration of dendritic cells
to lymph nodes [33]. Hoshino et al [34] found that the expression
of CCR8 was specifically up-regulated by CCL1 stimulation of
peritoneal macrophages, which may lead to cell aggregation at a
site of tissue damage. In the lungs, CCL1 expression was up-
regulated in Mycobacterium bovis purified protein derivative (PPD)
induced granulomas [35]. In this study, we found that CCL1
expression was induced by Mtb and TLR ligands in several
monocyte/macrophage lineages. Furthermore, we found that its
expression was MyD88-dependent when cells were stimulated with
LPS or Mtb. Genetic variation leading to the loss or alteration of
CCL1 function may influence the ability of T cells, monocytes and
dendritic cells to migrate to the site of infection, aggregate into
granulomas and develop an effective immune response. This may
result in inadequate containment of the bacterium and allow
unimpeded bacterial growth leading to pulmonary disease.
With currently available tools, clinicians are unable to identify
the subset of latently infected patients who will develop active
disease. Furthermore, there are no techniques available to
prospectively identify individuals at risk for the devastating
consequences of TBM versus more treatable forms of TB such
as localized pulmonary disease. Further studies in this area could
lead to tests that could alter treatment algorithms with more
accurate prognostic information. In addition, such studies may
lead to novel molecular insight into TB pathogenesis.
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